<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Site da Brakke Consulting</provider_name><provider_url>https://brakkeconsulting.com/pt</provider_url><author_name>Amanda McDavid</author_name><author_url>https://brakkeconsulting.com/pt/author/amanda/</author_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="mQdMTaSklh"&gt;&lt;a href="https://brakkeconsulting.com/pt/thoughts-on-third-quarter-earnings/"&gt;Considera&#xE7;&#xF5;es sobre os resultados do terceiro trimestre&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/pt/thoughts-on-third-quarter-earnings/embed/#?secret=mQdMTaSklh" width="600" height="338" title="&#x201C;Thoughts on Third Quarter Earnings&#x201D; &#x2014; Brakke Consulting Website" data-secret="mQdMTaSklh" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script&gt;
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
&lt;/script&gt;</html><description>Third quarter 2026 earnings season is generally over. Zoetis continues to dominate the industry in terms of overall sales with 3Q26 YTD total sales that are almost 37% larger than the next biggest company. However, industry growth generators have clearly shifted. For the largest public companies, 3Q YTD growth on a constant currency and scope basis was as follows: IDEXX (+10%), Elanco (+9%), Merck (+5.1%), Virbac (+7.9%), Vetoquinol (+5.4%) and Zoetis (-1%). The main shift in growth performance can be attributed to innovation. Both Elanco and Merck have invested in developing new product entrants targeting market segments that Zoetis has dominated, launching competitive products in the combination and long-acting parasiticide, and dermatology segments. Another aspect of bolstering performance is product line balance. Elanco has the most balanced product line with a 51% companion animal (CA) /48% livestock (L) split into segments. Merck&#x2019;s split is 40/60 and Zoetis is 67/32. Most industries, including animal health, run in cycles. Diversification is important to weather the ups and downs of the various market segments. In the end, it looks like the industry will deliver overall growth rates in line with historical averages. To learn more about industry performance and trends, please join the Brakke team for the Annual Industry Overview presentation at both VMX in Orlando and WVC in Las Vegas in earlyView Full Post;</description></oembed>
